tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

IMTX Stock Latest News

Immatics Advances PRAME Cell Therapy and Expands Oncology Pipeline
Company AnnouncementsImmatics Advances PRAME Cell Therapy and Expands Oncology Pipeline
6d ago
6K
IMTX
Immatics price target lowered to $13 from $15 at BofA
PremiumThe Fly
Immatics price target lowered to $13 from $15 at BofA
12d ago
IMTX
Immatics Faces Termination of Key Collaboration with Bristol Myers Squibb
PremiumCompany Announcements
Immatics Faces Termination of Key Collaboration with Bristol Myers Squibb
1M ago
6K
IMTX
Immatics N.V. Reports Strong Q3 2024 Progress and Financials
PremiumCompany Announcements
Immatics N.V. Reports Strong Q3 2024 Progress and Financials
2M ago
IMTX
Immatics moved to Buy from Not Rated at Goldman Sachs
PremiumThe Fly
Immatics moved to Buy from Not Rated at Goldman Sachs
2M ago
IMTX
Immatics price target lowered to $15 from $16 at BofA
PremiumThe FlyImmatics price target lowered to $15 from $16 at BofA
2M ago
IMTX
Immatics price target lowered to $18 from $19 at Leerink
Premium
The Fly
Immatics price target lowered to $18 from $19 at Leerink
2M ago
IMTX
Immatics announces clinical data on TCER IMA402 targeting PRAME
Premium
The Fly
Immatics announces clinical data on TCER IMA402 targeting PRAME
2M ago
IMTX
Immatics Sees Revenue Surge Despite R&D Expenses
PremiumCompany Announcements
Immatics Sees Revenue Surge Despite R&D Expenses
2M ago
6K
IMTX
Immatics sees cash runway into 2H27
PremiumThe Fly
Immatics sees cash runway into 2H27
2M ago
IMTX
Immatics reports Q3 EPS (EUR 0.11) vs. (EUR 0.32) last year
PremiumThe Fly
Immatics reports Q3 EPS (EUR 0.11) vs. (EUR 0.32) last year
2M ago
IMTX
IMTX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
IMTX Upcoming Earnings Report: What to Expect?
2M ago
IMTX
Immatics Unveils Promising TCR-T Therapy Developments
PremiumCompany AnnouncementsImmatics Unveils Promising TCR-T Therapy Developments
2M ago
6K
IMTX
Immatics N.V. Announces Major Share Offering
Premium
Company Announcements
Immatics N.V. Announces Major Share Offering
3M ago
6K
IMTX
Immatics 16.25M share Spot Secondary priced at $9.25
Premium
The Fly
Immatics 16.25M share Spot Secondary priced at $9.25
3M ago
IMTX
Immatics announces proposed $150M underwritten public offering
PremiumThe Fly
Immatics announces proposed $150M underwritten public offering
3M ago
IMTX
Immatics files automatic mixed securities shelf
PremiumThe Fly
Immatics files automatic mixed securities shelf
3M ago
IMTX
Immatics Advances IMA203 to Phase 3 Trial in Melanoma
PremiumCompany Announcements
Immatics Advances IMA203 to Phase 3 Trial in Melanoma
3M ago
6K
IMTX
Immatics provides update on Phase 1b trial of ACTengine in melanoma
PremiumThe Fly
Immatics provides update on Phase 1b trial of ACTengine in melanoma
3M ago
IMTX
Immatics initiated with an Overweight at Piper Sandler
PremiumThe FlyImmatics initiated with an Overweight at Piper Sandler
3M ago
IMTX
Immatics Reveals Promising IMA401 Trial Results
Premium
Company Announcements
Immatics Reveals Promising IMA401 Trial Results
4M ago
6K
IMTX
Immatics presents TCER IMA401 data at ESMO
Premium
The Fly
Immatics presents TCER IMA401 data at ESMO
4M ago
IMTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >